Stem Cell Therapeutics Corp. Announces Appointment of Barry Herring as New Chief Financial Officer
January 12 2009 - 10:29AM
Marketwired
Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) today
announced that Mr. Barry Herring has been appointed as the new Vice
President of Finance and Chief Financial Officer (CFO), effective
January 1, 2009. Mr. Mark Wayne has resigned as CFO but will remain
on the Board of Directors of SCT as Chairman.
Mr. Herring has 25 years experience as an accounting executive
for companies in Canada and the United States. He has been a senior
executive in public and private corporations within the energy and
mining sector. Prior to joining SCT, Mr. Herring was the President,
CFO and Director of Atlas Minerals Inc. Prior thereto he was the
CFO of Velo Energy Ltd., a start-up Oil and Gas Exploration
Company. He has served as Vice President of Finance and CFO for the
following companies, TerraWest Energy Corp., Hawker Resources Inc.,
and Southward Energy Ltd.
Mr. Herring became a Chartered Accountant in 1983 from the
Institute of Chartered Accountants of Alberta. He started his
career in accounting in 1981 at Price Waterhouse. In 1987, Mr.
Herring joined Oakwood Petroleum and worked as a corporate
accountant until joining Calpine Natural Gas Ltd. in 1989 where he
held increasingly senior positions until his departure in 2001.
In addition to his corporate experience, Mr. Herring has taught
accounting and tax at the post secondary level and chaired several
committees on Information Systems development and
implementation.
Dr. Alan Moore, President and CEO of SCT commented as
follows:
"We are very excited to add Mr. Barry Herring to the SCT
executive team. I feel his knowledge and expertise in finance as
well as his experience with start-up companies will be a great
asset to the Company."
SCT has issued 800,000 stock options to Mr. Herring at an
exercise price of C$0.10 per share in connection with his
appointment to the Executive team. These options will expire no
later than January 1, 2014 subject to applicable vesting
provisions. These options were awarded in accordance with the
Corporations Stock Option Plan.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair neurological function lost due to disease or injury. SCT's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024